Interleukin‐2 Deprived State of Regulatory T cells and Their Recovery by Low‐Dose Interleukin‐2 in Patients With Inflammatory Myopathies
Authors' conclusion
Our data suggest that shortage of IL-2 is pathophysiologically relevant in PM/DM.
Study context
- Population
- Patients with PM or dermatomyositis (DM) and healthy controls
- Participants
- 20 vs 19
- Comparison
- PM/DM vs healthy controls; in vitro stimulation with different concentrations of recombinant human IL-2
- PM/DMn = 20
- Healthy controls (HC)n = 19reference
- Outcome
- Treg subset frequencies
Methodological detailscase-control comparison, in vitro stimulation, case series of low-dose IL-2 therapy
- Case-control comparison
- In vitro stimulation
- Case series of low-dose IL-2 therapy
Main finding
As reported in the abstract
- PM/DM vs HC: P = 0.0052
- PM/DM vs HC: P = 0.0661
Further findings
Treg subset frequencies in active myositis
- CD25hi Treg reduced, particularly in active myositis
- P = 0.0036
- CXCR5+ Treg reduced, particularly in active myositis
- P = 0.0335
In vitro low-dose IL-2 stimulation of peripheral blood mononuclear cells (PBMC) · 24 hours
- Increase in CD25hi Treg subset
- P < 0.05
- Augmented Messenger RNA (mRNA) expression of several immunoregulatory molecules
- P < 0.05
- PBMC from eight patients; mRNA in n = 6
Low-dose IL-2 therapy in 2 patients with refractory PM/DM · eight weeks
- Decreases in muscle enzymes, accompanied by sustained expansion of CD25+ Treg
Original publication
Interleukin‐2 Deprived State of Regulatory T cells and Their Recovery by Low‐Dose Interleukin‐2 in Patients With Inflammatory Myopathies. Arthritis Rheumatol. Published 28 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →